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https://doi.org/10.1016/j.stemcr.2019.05.005SUMMARYGain of 20q11.21 is one of themost common recurrent genomic aberrations in human pluripotent stem cells. Although it is known that
overexpression of the antiapoptotic gene Bcl-xL confers a survival advantage to the abnormal cells, their differentiation capacity has not
been fully investigated. RNA sequencing of mutant and control hESC lines, and a line transgenically overexpressing Bcl-xL, shows that
overexpression of Bcl-xL is sufficient to causemost transcriptional changes induced by the gain of 20q11.21. Moreover, the differentially
expressed genes inmutant and Bcl-xL overexpressing lines are enriched for genes involved in TGF-b- and SMAD-mediated signaling, and
neuron differentiation. Finally, we show that this altered signaling has a dramatic negative effect on neuroectodermal differentiation,
while the cells maintain their ability to differentiate to mesendoderm derivatives. These findings stress the importance of thorough ge-
netic testing of the lines before their use in research or the clinic.INTRODUCTION
Human embryonic stem cells (hESCs) can be cultured
in vitro for extended periods of time without losing their
ability to differentiate into all three germ layers. Their
terminally differentiated derivatives have become a potent
tool in disease modeling and may play important future
roles in regenerative medicine, toxicology tests, and drug
screening. As all these applications will require between
millions and billions of cells, prolonged culture periods
are almost inevitable (Avior et al., 2016; Serra et al.,
2012). hESC cultures tend to acquire chromosomal abnor-
malities that vary in size from small structural variants to
full chromosome gains and losses (Keller et al., 2018;
Nguyen et al., 2013). Several aberrations are known to be
recurrent, such as gains of chromosomes 1, 12, 17, and X,
or parts thereof (Amps et al., 2011; Baker et al., 2007;
Cowan et al., 2004; Draper et al., 2004; Herszfeld et al.,
2006; Inzunza et al., 2004; Maitra et al., 2005; Mitalipova
et al., 2005; Yang et al., 2010). Of special interest is the
gain of 20q11.21 found in more than 20% of lines world-
wide (Amps et al., 2011; Laurent et al., 2011; Lefort et al.,
2008; Na¨rva¨ et al., 2010; Spits et al., 2008; Wu et al.,
2008). The smallest region of amplification includes the
antiapoptotic gene BCL2L1 (Amps et al., 2011). We, and
others, have found that the mutant cells overexpress Bcl-
xL, the predominantly expressed isoform of BCL2L1. ThisStem C
This is an open access article under the Cconfers a survival advantage to these mutant cells that al-
lows them to quickly take over the culture (Avery et al.,
2013; Nguyen et al., 2014).
Although it is generally assumed that chromosome
abnormalities influence the functional characteristics of
hESCs, particularly on differentiation, only a handful of
reports on this topic have been published (Ben-David
et al., 2014; Fazeli et al., 2011; Herszfeld et al., 2006;
Keller et al., 2018; Werbowetski-Ogilvie et al., 2009; Yang
et al., 2008). Undifferentiated chromosomally abnormal
hESCs have been found to acquire characteristics such
as increased cloning efficiency, decreased population
doubling times (Fazeli et al., 2011), increased capacity for
cell proliferation and self-renewal, antiapoptotic properties
(Baker et al., 2007; Yang et al., 2008), growth factor inde-
pendence, and an increase in teratoma-initiating cells
(Werbowetski-Ogilvie et al., 2009). These studies also
demonstrated that hESCs carrying chromosomal abnor-
malities show altered gene expression patterns when
compared with normal cell lines, while retaining their—
possibly reduced—differentiation capacity (Fazeli et al.,
2011; Werbowetski-Ogilvie et al., 2009). Karyotypically
abnormal hESCs tend to produce immature teratomas
when injected in vivo, containing a higher proportion of
poorly differentiated or undifferentiated cells when
compared with normal hESCs (Herszfeld et al., 2006; Wer-
bowetski-Ogilvie et al., 2009; Yang et al., 2008). Theseell Reports j Vol. 13 j 163–176 j July 9, 2019 j ª 2019 The Author(s). 163
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studies also show an upregulation of a number of onco-
genes, concurrent with a downregulation of genes related
to differentiation, which has been interpreted as a first
step toward malignant transformation (Gopalakrishna-Pil-
lai and Iverson, 2010; Werbowetski-Ogilvie et al., 2009;
Yang et al., 2008). Furthermore, similarly tomalignant can-
cer cells, mutant hESCsmigrate faster in three-dimensional
collagen gels than normal hESCs (Werbowetski-Ogilvie
et al., 2009). Overall, these studies were limited in that
they were carried out on a small number of lines carrying
different abnormalities, or even one hESC line carrying a
20q11.21 duplication (Werbowetski-Ogilvie et al., 2009),
while only one study consistently described one type of ab-
erration using multiple carrier lines (Ben-David et al.,
2014).
Our aimwas to elucidate if and how the gain of 20q11.21
impacts the differentiation capacity of hESCs. This is of
particular importance given that most of these gains fall
below the size detection limit of conventional G-banding,
which is still the most commonly used method for moni-
toring the karyotype of human pluripotent stem cells
(hPSCs). We studied nine hESC lines, of which four carry
a gain of 20q11.21 and one line transgenically overex-
presses Bcl-xL. Two other genes present in the smallest
common region of gain, ID1 and HM13, are not further
considered in this work because, as already described, ID1
protein level does not differ in the mutant cells as
compared with normal lines and the function of HM13 is
limited and relates to immune function, making it a poor
candidate in relation to differentiation (Nguyen et al.,
2014).
Our results show that hESC lines carrying a 20q11.21
amplification have a transcriptome that is significantlyFigure 1. HESCS with a Gain of 20q11.21 Show an Altered Transc
(A) Graphical representation of the chromosomal content of the mu
enlarged to show the breakpoints and region of gain. From outside
Regions of gain are represented in red, loss in blue.
(B) Copy number of the 20q11.21 region established by qPCR in all s
(C and D) (C) BCL2L1 mRNA (n = 3) and (D) Bcl-xL protein levels in
sandwich ELISA. Data are shown as means ± SEM (n = 3).
(E and F) (E) Unsupervised cluster analysis and (F) multidimensional
with a count per million greater than one in at least two samples.
(G and H) Volcano plots of the differential gene expression analysis wi
versus mutant (G) and control versus VUB03_BcL-xL (H).
(I and J) Venn diagrams comparing the deregulated genes in VUB03_
upregulated genes and (J) the downregulated genes.
(K) Venn diagram comparing the deregulated genes in all mutant lin
(L) Shows the percentage of deregulated genes that are unique or co
(M) Smoothened gene expression data of all genes on chromosome 20
the region of chromosomal gain, the red line the region of loss.
(N) Gene set enrichment analysis using the MSigDB database C1, for th
plot shows the chromosomal positions with significant enrichment in
enrichment score (NES) and in red, with a positive NES.different from their chromosomally normal isogenic coun-
terparts as reflected in multiple deregulated pathways, in
particular for transforming growth factor b (TGF-b)- and
SMAD-mediated signaling genes.We show that Bcl-xL over-
expression is the main driver of these changes. Finally, we
show that this results in a strong impairment of ectodermal
differentiation in the mutant cells, while their capacity for
differentiation into mesendodermal derivatives remains
intact.RESULTS
hESCs with a Gain of 20q11.21 Show an Altered
Transcriptomic Profile Similar to the Bcl-xL
Overexpressing Line
As a first step, we investigated the transcriptomic differ-
ences between lines with a gain of 20q11.21 and their
genetically normal counterparts, and the role of Bcl-xL
in these differences. Our study included nine hESC
lines derived and kept in culture in our laboratory: four
lines with gains of 20q11.21 (VUB01_mt, VUB02_mt1,
VUB02_mt2, and VUB03_mt) of different sizes, their
chromosomally balanced isogenic counterparts (VUB01,
VUB02, and VUB03), an additional normal line
(VUB14) and a line transgenically overexpressing Bcl-xL
(VUB03_Bcl-xL) characterized by Nguyen et al. (2014)
(Table S1). The karyotypes of all our lines were assessed
by array comparative genomic hybridization (aCGH)
before the experiments and the number of copies of
20q11.21 was established by real-time qPCR. Figure 1A
shows a diagram of the chromosomal content of the
mutant lines with a magnified chromosome 20. The sizeriptomic Profile Similar to VUB03_BcL-xL
tant lines in this study, established by aCGH. Chromosome 20 is
to inside: VUB01_mt, VUB02_mt1, VUB02_mt2, and VUB03_mt.
tudied lines (n = 3).
mutant and control hESCs and in VUB03_BcL-xL as established by
scaling plot of dimension 1 versus dimension 2 of all coding genes
th a cutoff value of jlog2 fold changej > 1 and FDR < 0.05 for control
BcL-xL with those deregulated in the mutant lines. (I) Shows the
es.
mmon, or common between at least two lines.
, for the four lines carrying a gain of 20q11.21. The blue lines show
e deregulated genes in the mutant lines and in VUB03_BcL-xL. The
deregulated genes. In blue are regions with a negative normalized
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of the amplification ranged between 0.9 and 4 Mb with
an identical proximal and a variable distal breakpoint.
VUB02_mt2 carried an isochromosome 20 (loss of the p
arm and duplication of the q arm). All the control lines
had a fully balanced genetic content, and VUB03_BcL-xL
also carried a gain of 1q32.1q41. The exact breakpoints of
the chromosomal abnormalities, along with the passage
range of each hESC line used in the study can be found
in Table S1. The gain of 20q11.21 is often an amplification
ranging from three to five copies rather than a simple
duplication (Figure 1B). The Bcl-xL mRNA levels in the
overexpressing line were nearly 70 times higher than in
the control lines and were 10-fold that of VUB01_mt and
VUB02_mt1 (Figure 1C), although the protein levels were
similar to those of VUB02_mt1 (Figure 1D).
We carried out RNA sequencing on two to five replicates
per line collected fromdifferent dishes.We only considered
coding genes with a count per million greater than one in
at least two samples. Unsupervised hierarchical cluster
analysis using all expressed genes shows that the mutant
hESC lines and the VUB03_Bcl-xL line display an expres-
sion motif different from the control lines, resulting in
the clustering of the mutant and the Bcl-xL lines separate
from the control lines (Figure 1E). The same pattern ap-
pears in the multidimensional scaling plot generated
considering all expressed genes, showing the clustering of
the control lines separate from the mutant lines and
together with VUB03_BcL-xL (Figure 1F), demonstrating
that overexpression of Bcl-xL is sufficient to result in a tran-
scriptome close to that of a mutant line. Furthermore, the
clustering pattern of VUB03_Bcl-xL suggests that the
impact of the overexpression of Bcl-xL on the transcrip-
tome of the cells is stronger than that of the gain of
1q32.1q41, which the line also carries.
Differential gene expression analysis with a cutoff value
of jlog2 fold changej > 1 and false discovery rate q value
(FDR) < 0.05 shows 1,431 upregulated and 1,505 downre-
gulated genes in mutant versus control lines. VUB03_BcL-
xL shows 1,968 upregulated and 2,206 downregulated
genes compared with the normal lines (Figures 1G and
1H). Approximately 65% of the genes that are differentially
expressed by the mutant lines are in common with the de-
regulated genes in VUB03_BcL-xL (Figures 1I and 1J). Next,
we plotted the overlap in deregulated genes of the mutant
lines compared with the control lines. All mutant lines
have a subset of deregulated genes that are unique to the
line, representing between 15% and 32% of the differential
gene expression. Conversely, 22% to 30% of genes were
common to all lines, and between 44% and 53% were in
common with at least one other mutant line (Figures 1K
and 1L). This suggests that a core of 889 genes are deregu-
lated due to the overexpression of genes located in the
common region of 20q11.21 irrespective of the line-to-166 Stem Cell Reports j Vol. 13 j 163–176 j July 9, 2019line variation. Furthermore, 763 of these 889 genes
(85.8%) are also deregulated in the Bcl-xL overexpressing
line, strongly suggesting that Bcl-xL plays a predominant
role in the transcriptomic profile of the cells with a gain
of 20q11.21.
Finally, we mapped the differential gene expression to
chromosomal position. First, we calculated and plotted
the smoothened log2 fold-change expression of all genes
on chromosome 20 for each mutant line individually,
and compared this with the control lines as a group (Fig-
ure 1M, raw data in Figure S1). In VUB01_mt, VUB02_mt1,
and VUB02_mt2 the overexpression of genes located in the
region of gain of chromosome 20 is clearly observed.
VUB03_mt carries the smallest region of gain and no differ-
ences can be observed in the expression in that region. Sec-
ond, we used the gene set enrichment analysis using the
MSigDB database C1 for the deregulated genes in the
mutant lines and in VUB03_BcL-xL. The mutant lines
have a positive enrichment score for 20q, which is absent
in VUB03_BcL-xL. However, there is a similar enrichment
score across the genome of the mutant lines and
VUB03_BcL-xL, showing 16 of the 18 enriched regions to
be in common (Figure 1N). These results illustrate a num-
ber of salient points. Expectedly, the higher copy number
has an effect on the gene expression of most—but not
all—genes in the amplified region, which is why gene
expression data can be used to karyotype cells (Ben-David
et al., 2013). However, smaller gains fall under the detec-
tion level unless they induce very strong gene expression
changes. More importantly, a variant copy number of one
region can strongly act in trans on the expression of genes
located on other chromosomes.
In summary,mutant lines show a different transcriptome
from their normal counterparts, which can largely be
attributed to the overexpression of Bcl-xL. The overexpres-
sion of other genes located within the mutation has a min-
imal, if any, effect.
The 20q11.21 Mutation Affects TGF-b- and SMAD-
Mediated Signaling through Bcl-xL Overexpression
In a next step, we carried out pathway analysis using mul-
tiple bioinformatic tools. First, we carried out ingenuity
pathway analysis (IPA) using all genes with a jlog2 fold
changej > 1 and FDR < 0.05, for both the mutant versus
control groups, and the VUB03_BcL-xL line versus a con-
trol group. This analysis predicts the state of upstream reg-
ulators based on the expression of their downstream tar-
gets. IPA considers a pathway to be activated with a Z
score >2, and inhibited with a score less than 2. When
the p value is significant and the activation Z score is
between 2 and 2, it is considered to be significantly
affected, without being able to establish whether it is acti-
vated or inhibited. In our dataset, the activation score in
Figure 2. Pathway Analysis in hESCs with a Gain of 20q11.21 and in VUB03_BcL-xL
(A) Ingenuity Pathway Analysis of the upstream regulators of pathways with an activation score between2 and 2 and a p value < 0.05 in
the wild-type (WT) versus mutant (MT) lines and their behavior in VUB03_BcL-xL.
(B) DAVID Enrichment Analysis of the 1,000 top deregulated genes in the mutant group and VUB03_BcL-xL. In parenthesis are the gene-
ontology term numbers.
(C and D) Gene set enrichment analysis using the MSigDB C2 library (C) and Enrichr-based prediction of protein-protein interactions for
transcription factors (D). All results are statistically significant with a p value < 0.05 unless the value is given. All the analyses were
performed using the differentially expressed genes between WT versus mutant group and WT versus VUB03_BcL-xL with a cutoff value of
jlog2 fold changej > 1 and FDR < 0.05.VUB03_BcL-xL follows that of the mutant lines in all cases,
and, in the case of pathways not reaching the Z score >2 or
less than 2, the p value is still always significant
(Figure 2A).
We then subjected the 1,000 genes with the highest log
fold change in absolute value (563 up- and 437 downregu-
lated for the 20q11.21 lines, 485 up- and 515 downregu-
lated for VUB03_BcL-xL) to DAVID functional annotation
enrichment analysis. The analysis retrieved a total of 75 an-
notations, of which we selected those gene ontology terms
referring to cellular processes and that had a fold enrich-
ment >2, and a p value < 0.05 in at least one of the groups
(Figure 2B). Interestingly, the deregulated genes in both
mutant lines and VUB03_BcL-xL are enriched for factors
in the TGF-b and SMAD signaling, as well as in genes
involved in neuron differentiation and cochlea morpho-
genesis, which are full or partial ectodermal derivatives,
respectively. Next, we carried out gene set enrichment anal-
ysis using the C2 library (full list in Table S2). The resultsdid not yield any significantly deregulated pathways
when using the Kyoto Encyclopedia of Genes and Ge-
nomes, but revealed 17 significantly enriched processes as
annotated in the Reactome library. These can broadly be
categorized into related to mRNA processing, cell cycle,
and TGF-b and SMAD signaling (Figure 2C).
Subsequently, we analyzed the transcription factor
enrichment and protein-protein interactions in the differ-
entially expressed genes in the mutant lines and in
VUB03_BcL-xL with a jlog2 fold changej > 1 and FDR <
0.05, using Enrichr (Chen et al., 2013; Kuleshov et al.,
2016). Our datasets show a negative Z score for protein
interaction with SMAD2 (Figures 2D and S2).
Overall, these results suggest that hESCs with a gain of
20q11.21 appear to have a perturbed TGF-b and SMAD
signaling and that Bcl-xL overexpression is responsible for
most of these changes. Given the pivotal role of TGF-b
and SMAD signaling in gastrulation and early lineage
commitment, we hypothesized that the gain of 20q11.21Stem Cell Reports j Vol. 13 j 163–176 j July 9, 2019 167
Figure 3. Bcl-xL Overexpression Due to a Gain of 20q11.21 Results in Impaired Neuroectoderm Differentiation
(A) Examples of immunostaining for PAX6 (green) and POU5F1 (red) in mutant and control lines and in VUB03_BcL-xL, after 4 days of
neuroectoderm differentiation.
(B) Percentage of PAX6- and POU5F1-positive cells. The mutant lines and VUB03_BcL-xL yield less PAX6-positive cells than the control
lines.
(C) Relative mRNA expression as measured by qPCR for ectoderm markers PAX6 and SOX1 (n = 3–6). Data are shown as means ± SEM, each
dot represents an independent differentiation experiment and the horizontal bars with asterisks represent statistical significance between
samples (p < 0.05, t test).may have an impact on the differentiation capacity of the
cells.
Gain of 20q11.21 Results in Impaired Neuroectoderm
Differentiation
We first assessed the neuroectodermal differentiation effi-
ciency of all our control and mutant lines and that of
VUB03_BcL-xL. We performed a 4-day induction protocol
recapitulating neuroectoderm commitment using Noggin
and SB431542, both of which are TGF-b superfamily antag-
onists (Chambers et al., 2009; Chetty et al., 2013). We
differentiated all our lines in three to six independentdiffer-
entiation experiments to ensure the reproducibility and
consistency of the experiments. At the fourth day of neuro-168 Stem Cell Reports j Vol. 13 j 163–176 j July 9, 2019ectoderm induction, we analyzed the mRNA of markers for
each lineage (endo-, neuroecto-, and mesoderm), and the
stem cell markers POU5F1 and NANOG. We stained for
PAX6 as neuroectodermal marker and POU5F1 as pluripo-
tency marker and quantified the number of positive cells
(Figure 3A). The data show that all samples derived from
mutant lines and VUB03_BcL-xL display statistically signif-
icantly lower levels of PAX6 and SOX1 mRNA (Figure 3C),
and between 1.8 and 3.3 times less PAX6-positive cells (Fig-
ures 3B and S3). Next to the neuroectoderm and stem cell
markers, we also tested for the expression of mesendoderm
markers (Figure S3). The results show that,while themutant
cells do exit the pluripotent state, they do not differentiate
into any early, specific germ line detectable with the
Figure 4. Control and Mutant Lines and VUB03_BcL-xL Equally Differentiate to Mesendoderm Derivatives
(A) Representative examples of immunostaining for T (green) and POU5F1 (red) in control (VUB01_wt) and mutant (VUB01_mt) lines after
mesendoderm induction.
(B) Percentage of T/POU5F1 double-positive (mesendoderm cells) and POU5F1-only positive cells.
(C) Examples of immunostaining for SOX17 (green) and POU5F1 (red) in control (VUB01_wt and VUB03_wt) and mutant (VUB01_wt and
VUB03_mt) lines, and VUB03_BcL-xL after definitive endoderm differentiation.
(legend continued on next page)
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markers we used. The fact that VUB03_BcL-xL follows the
same pattern as the mutant cells, showing practically no
expression of neuroectodermal markers after the 4-day in-
duction, supports the hypothesis that the overexpression
of Bcl-xL alone is sufficient to cause this abnormal differen-
tiation. Finally, we also differentiated control and mutant
hESCs to neuroectoderm in a 12-day protocol, confirming
the difference between the control andmutant hESCs after
extended differentiation (Figure S3).
Mutant and Control Lines Equally Differentiate
toward Mesendoderm Derivates
Finally, we assessed the impact of the mutation and Bcl-xL
overexpression on mesendodermal lineage commitment
using a 24-h protocol that drives the differentiation
through the first events of the primitive streak formation
by TGF-b and WNT activation. We measured the protein
levels of Brachyury (T) in our lines and found that they
all underwent mesendoderm induction with an equally
good efficiency (Figures 4A and 4B). To investigate the abil-
ity of the lines to further commit to derivatives of this germ
layer, we directed the cells toward definitive endoderm.We
differentiated all eight lines (with three to six replicates per
line) and evaluated the gene expression at the mRNA and
protein levels. Figure 4E shows the mRNA expression re-
sults, which are in line with the immunostaining results
for SOX17 and POUF51 (Figures 4C and 4D). All the lines
increased their expression of endoderm markers, and no
consistent expression of markers for other lineages was
observed (Figure S5). NANOG and POU5F1 were overall
slightly but not completely downregulated, as expected
given their important roles in early endoderm differentia-
tion (Teo et al., 2011; Ying et al., 2015). Overall, in all cases,
control and mutant lines as well as VUB03_BcL-xL readily
and similarly differentiated to definitive endoderm.
Downregulation of CHCHD2 Is a Transcriptomic
Marker for the Gain of 20q11.21
The deregulation of the TGF-b and the SMAD signaling
suggested by the DAVID analysis and the well-established
relationship of this pathway to pluripotency and ectoderm
differentiation prompted us to further investigate the
differentially expressed genes to understand the driving
mechanism for this deregulation. For this, we annotated
the function of the top 100 differentially expressed genes
(Table S3) in both mutant and Bcl-xL overexpressing cells,
and searched the literature for their potential relationship
to Bcl-xL and the TGF-b/SMAD signaling. The most inter-(D) Percentage of SOX17- and POU5F1-positive cells.
(E) Relative mRNA expression as measured by qPCR (n = 3 to
independent differentiation experiment and the horizontal bars w
(p < 0.05, t test).
170 Stem Cell Reports j Vol. 13 j 163–176 j July 9, 2019esting candidate in this list is CHCHD2 because the protein
binds Bcl-xL, resulting in a decreased oligomerization of
apoptotic activator Bax (Liu et al., 2015). Furthermore,
low levels of CHCHD2 have been mechanistically linked
to disrupted TGF-b/SMAD signaling and decreased neuro-
ectodermal commitment in hPSCs (Zhu et al., 2016). Our
RNA sequencing data showed that CHCHD2 is strongly
downregulated in the lines with a gain of 20q11.21 and
in VUB03_BcL-xL. Hence, we decided to investigate if
CHCHD2was effectively themediator of the decreased neu-
roectoderm commitment of the mutant cells.
We validated the CHCHD2 RNA sequencing findings by
measuring the mRNA and protein levels in normal and
mutant lines as well as VUB03_BcL-xL. All mutant lines
and VUB03_BcL-xL showed statistically significantly lower
levels of CHCHD2 at the mRNA level, while the endoge-
nous expression levels varied up to a 4-fold change among
the control lines (Figure 5A). Immunocytochemistry of
normal and mutant lines and VUB03_BcL-xL showed
absence of CHCHD2 protein in the mutant and
VUB03_BcL-xL cells (Figure 5B). To assess if this downregu-
lation affected solely the pluripotent state, we differenti-
ated the VUB03_wt, VUB03_mt, and VUB03_BcL-xL
to neuroectoderm and definitive endoderm. Figure 5C
shows the real-time qPCR results showing thatCHCHD2 re-
mains stably downregulated after differentiation in both
VUB03_mt and VUB03_BcL-xL.
To functionally address the potential link between
CHCHD2 downregulation and decreased neuroectoderm
commitment, we used small interfering RNA (siRNA) to
knockdown CHCHD2 in control hESCs, and mRNA trans-
fection to exogenously overexpress CHCHD2 in mutant
cells. Figure 6A shows the mRNA levels of CHCHD2 in un-
differentiated VUB01_wt cells 24, 48, and 72 h after trans-
fection, and Figure 6B shows the immunostaining for the
protein 72 h posttransfection. The results show downregu-
lation both at the mRNA and protein levels. We induced
neuroectoderm commitment in VUB01_wt treated with
siRNA against CHCHD2 as well as untreated cells and cells
treated with a nontargeting siRNA.WemeasuredCHCHD2,
PAX6, and SOX1 expression each day of a 4-day differenti-
ation. This experiment was repeated four times; the results
are shown in Figures 6C and 6D. We found that the knock-
down of CHCHD2 did not change the ability of the cells to
differentiate to neuroectoderm in any of the replicates. We
also exogenously overexpressed CHCHD2 in VUB01_mt
(Figure 6E) and measured the PAX6 and SOX1 expression
on day 0, 2, and 4 of neuroectoderm induction (Figure 6F).6). Data are shown as means ± SEM, each dot represents an
ith asterisks represent statistical significance between samples
Figure 5. Lines with a Gain of 20q11.21 Stably Downregulate CHCHD2 Due to Bcl-xL Overexpression
(A and B) (A) CHCHD2 expression as measured by qPCR in undifferentiated cells. All mutant lines show a significantly decreased expression
compared with their normal counterparts (n = 4–9). (B) CHCHD2 immunostaining (in green) in VUB01 showing the presence of the protein
in the control subline and its absence in the mutant subline.
(C) CHCHD2 expression as measured by qPCR in the three sublines of VUB03 (control, mutant, and VUB03_BcL-xL) in the differentiated
state. DE, definite endoderm; EC, neuroectoderm (n = 7–10).
(A and C) Data are shown as means ± SEM, each dot represents an independent differentiation experiment and the horizontal bars with
asterisks represent statistical significance between samples (p < 0.05, t test).In line with the siRNA data, the results show that exoge-
nous CHCHD2 expression does not rescue the effect of
the gain of 20q11.21.
In summary, while CHCHD2 is consistently downregu-
lated in mutant hESCs both before and after differentia-
tion, our results strongly suggest that it is not the link be-
tween the Bcl-xL upregulation in the mutant cells and
their decreased neuroectodermal commitment.DISCUSSION
The aim of our studywas to investigate the impact of one of
the most commonly found chromosomal abnormalities in
hPSCs, a gain of 20q11.21, on their differentiation capacity
(Amps et al., 2011). The awareness of genome instability in
hPSCs has increased in the past years, along with the real-
ization that we lack answers on what the functional conse-
quences of these mutations are on differentiating cells,
especially when considering clinical applications (Andrews
et al., 2017). Our work was prompted by the clear need for
systematic studies of the impact of recurrent chromosomal
abnormalities on the differentiation capacity and malig-
nant potential of hPSCs.
To reach our aim, we included fourmutant lines and their
isogenic normal counterparts, and one Bcl-xL overexpress-
ing line. Remarkably, transcriptomic analysis showed thatall mutant lines have a significantly different transcriptome
from their chromosomally normal isogenic counterparts,
and which is very similar to that of cells transgenically over-
expressing Bcl-xL. This is despite the fact that the mutant
lines carried different copy numbers, leading to a difference
in overexpression of genes within the region. This strongly
suggests that overexpression of Bcl-xL alone, which is also
the driver for the selective advantage of the cells in their un-
differentiated state (Avery etal., 2013;Nguyenetal., 2014), is
sufficient to explain themajority of transcriptomic changes.
Interestingly, an important part of the differential expres-
sionwas of genes related to the TGF-b- and SMAD-mediated
signaling, which led us to investigate the behavior of the
mutant hESCs during the lineage commitment to neuroec-
toderm andmesendoderm.Our differentiation experiments
show that the lines with a gain of 20q11.21 and those over-
expressingBcl-xLhavean impairedneuroectodermal lineage
commitment,withnodifferences in their capacity for differ-
entiation into mesendodermal derivatives.
Next, CHCHD2 was identified as a prime candidate link-
ing Bcl-xL to the transcriptomic changes, because it is
consistently downregulated in mutant cells and the pro-
tein binds Bcl-xL, resulting in a decreased oligomerization
of Bax (Liu et al., 2015). This downregulation may be
through a self-regulatory feedback loop, as CHCHD2 is
able to translocate to the nucleus to transactivate itself as
well as other genes that contain oxygen-responsiveStem Cell Reports j Vol. 13 j 163–176 j July 9, 2019 171
Figure 6. Knockdown and Overexpression of CHCHD2 Do Not Affect Neuroectoderm Differentiation
(A) CHCHD2 expression as measured by qPCR in VUB01_wt 24, 48, and 72 h after transfection with siRNA against CHCHD2 (n = 1).
(B) Representative immunostaining of untreated and transfected cells 72 h posttransfection (the CHCHD2 protein can be seen in green).
(C and D) CHCHD2 (C) and PAX6 and SOX1 (D) expression as measured by qPCR in VUB01 WT during a 4-day induction to neuroectoderm. NT,
nontargeting siRNA (n = 1).
(E) Immunostaining of untreated cells and after 72 h of exogenous CHCHD2 expression (in green).
(F) PAX6 and SOX1 expression as measured by qPCR in VUB01_mt during a 4-day induction to neuroectoderm in untreated, control (GFP)
and CHCHD2-overexpressing cells (n = 1).
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element sequences in their promoter region (Aras et al.,
2013; Grossman et al., 2017). Another interesting function
of CHCHD2 is its capacity to interact with the SMADs (2/
3/4) and thus modulate the transcription of TGF-b-medi-
ated target genes (Zhu et al., 2016). Zhu et al. also showed
that endogenous low levels of CHCHD2 in hPSCs result
in a decreased capacity for ectodermal differentiation.
The findings in our transcriptome analysis showing dereg-
ulation of both TGF-b/SMAD signaling and genes involved
in neural differentiation in hESCs with a 20q11.21 muta-
tion and Bcl-xL overexpressing cells are consistent with
the known functions of CHCHD2. Finally, the TGF-b/
SMAD signaling is known to have a pivotal role during
the first-lineage commitment (Sumi et al., 2008). We there-
fore carried out functional tests, assessing the impact on
neuroectoderm differentiation of siRNA knockdown of
CHCHD2 in control cells and CHCHD2mRNA transfection
in mutant cells. Unexpectedly, we found that CHCHD2
does not mediate the effect on differentiation under our
experimental conditions. We have no immediate explana-
tion for these differences, although it is worth noting that
Zhu et al. did not assess ectodermal differentiation in the
same manner as we did, i.e., using a TGF-b inhibitor. In
their work, the differentiation biaswas assessed using spon-
taneous differentiation without modulating the TGF-b
signaling, which may explain some of the differences we
see. Another point of interest is that, in the last part of their
work, they show that the use of the TGF-b inhibitor
SB431542 during differentiation cancels the effect of
downregulating CHCHD2 using siRNA. This conclusion is
based on qPCR results for PAX6 between control and
siRNA-treated cells. Although the authors found a statisti-
cally significant upregulation of PAX6, the relative fold
change was less than 0.3 which may be not biologically
relevant. This is in line with our results for siRNA CHCHD2
knockdown. Taken together, this suggests that, although
Zhu et al. clearly prove that CHCHD2 interacts with
SMAD4, the relationship between CHCHD2 and neuroec-
toderm commitment is less direct than hypothesized.
Nevertheless, this gene appears as an excellent transcrip-
tomic marker for the gain of 20q11.21.
In summary, our work shows the significant impact ge-
netic changes can have on hPSCs, and provides, to the
best of our knowledge, one of the few studies pinpointing
a specific effect of a recurrent aberration and identifies
the mechanisms behind it. The results of our study are of
particular importance when taking into account that the
20q11.21 amplification occurs in more than 20% of hPSC
lines worldwide and that G-banding as the most widely
used method for karyotyping fails to detect it. The muta-
tion may bias experimental data in a research setting if un-
noticed, although it is unlikely that it would be undetected
in a clinical setting, because in clinical trials the geneticscreening protocols are more stringent. Nevertheless, if
the mutation is in the process of culture take-over, it could
remain undetected and result in poor differentiation in the
clinically relevant cell types.EXPERIMENTAL PROCEDURES
hESC Lines and Culture
hESC were derived and characterized as described previously
(Mateizel et al., 2006, 2009). All lines are registered with the EU
hPSC registry (https://hpscreg.eu/). hESCs were cultured on dishes
coatedwith 10 mg/mL laminin-521 (Biolamina) inNutriStemhESC
XF medium (NS medium; Biological Industries) with 100 U/mL
penicillin/streptomycin (Thermo Fisher Scientific), and passaged
as single cells in a 1:10 to 1:100 ration using TrypLE Express
(Thermo Fisher Scientific) when 70%–80% confluent. The cells
were grown at 37C in 5% CO2. VUB03_BcL-xL was generated by
lentiviral transduction, as described by Nguyen et al. (2014) and
in the Supplemental Information.
A large bulk of frozen cells was generated for each line. After
thawing, the lines were used at the lowest passage possible (Table
S1), and were checked for the 20q11.21 amplification by copy-
number assay 3 to 4 passages after thawing.
aCGH
Oligonucleotide aCGH was carried out based on the protocol pro-
vided by the manufacturer (Agilent Technologies). A total of
400 ng of DNA was labeled with Cy3, while the reference DNA
(Promega) was labeled with Cy5. The samples are hybridized on
the microarray slide (4 3 44K Human Genome CGH Microarray,
Agilent Technologies). The slides were scanned using an Agilent
dual laser DNA microarray scanner G2566AA. Only arrays with
an SD % 0.20, signal intensity > 50, background noise < 5, and a
derivative log-ratio < 0.2 were taken into account. Cutoff values
were set at three consecutive probes with an average log2 ratio
over 0.3 for gains and of 0.45 for loss.
Gene Copy Number Using Real-Time qPCR
Copy-number quantificationwas performed on the ViiA 7 thermo-
cycler (Thermo Fisher Scientific), ViiA 7 software v.1.2 (Thermo
Fisher Scientific), and Applied Biosystems Copy Caller v.2.1. We
used the copy-number assays for RNAseP (4403326) as a reference
and POFUT1 (Hs02487189_cn) to assess the number of copies of
the 20q11.21 region.
RNA Sequencing
RNA (150 ng) was used to perform an Illumina sequencing
library preparation using the QuantSeq 30 mRNA-Seq Library
Prep Kits (Lexogen) according to manufacturer’s protocol.
During library preparation 17 PCR cycles were used. Libraries
were quantified by qPCR, according to Illumina’s protocol
‘‘Sequencing Library qPCR Quantification protocol guide,’’
version February 2011. A high-sensitivity DNA chip (Agilent
Technologies) was used to control the library’s size distribution
and quality. Sequencing was performed on a high-throughput
Illumina NextSeq 500 flow cell generating 75 bp single reads.Stem Cell Reports j Vol. 13 j 163–176 j July 9, 2019 173
Details on the bioinformatics processing can be found in the
Supplemental Information.
hESC Differentiation
The protocol for neuroectoderm was adapted from Chetty et al.
(2013) and Chambers et al. (2009). hESCs were passaged on lam-
inin-521, as described above, 1–2 days before EC differentiation in
a ratio of 50,000 cells per cm2 so that they were 90% confluent on
the starting day. The neuroectoderm differentiation medium was
refreshed daily, and consisted of KnockOut DMEM (Thermo
Fisher Scientific) with 10% KnockOut Serum Replacement
(Thermo Fisher Scientific) and supplemented with 500 ng/mL Re-
combinant Human Noggin Protein (R&D Systems) and 10 mM
SB431542 (Tocris). Endoderm differentiation was carried out us-
ing a protocol based on Sui et al. (2012). hESCs were passaged
on laminin-521, as described above, 1–2 days before differentia-
tion in a ratio of 30,000 cells per cm2 so that they were
80%–90% confluent on the starting day. Definitive endoderm
differentiation medium contains RPMI 1640 supplemented by
GlutaMAX (Thermo Fisher Scientific), 0.5% B27 supplement
(Thermo Fisher Scientific), 100 ng recombinant human/mouse/
rat activin A (R&D Systems) and 3 mM CHIR99021 (Stemgent).
One day later the medium was changed to differentiation me-
dium without CHIR99021 and the cells were cultured for 2
more days. For mesendoderm induction, the same protocol as
for endoderm was used, for 1 day.
Protein and mRNA Analysis
Real-time qPCR was carried out on a ViiA 7 thermocycler (Thermo
Fisher Scientific) and using standard protocol as provided by the
manufacturer. Details on the probes, assays and primers are listed
in the Supplemental Information. Sandwich ELISA was conducted
using the human total Bcl-xL ELISA kit for Bcl-xL (DuoSet IC, R&D
Systems) following the manufacturer’s protocol. All samples were
analyzed in triplicate. Immunostaining was carried out on cells
fixed and permeabilized with 4% paraformaldehyde and 100%
methanol (Sigma-Aldrich), and blocked with fetal bovine serum
(Thermo Fischer Scientific). The list with antibodies can be found
in the Supplemental Information. Imaging was performed on a
LSM800 confocal microscope (Carl Zeiss), and cell counts were
done using the Zen 2 (blue edition) imaging software.
Statistics
Data are presented as means. Unpaired two-tailed t test (GraphPad
Prism 5.0b) was used to determine significance between groups.
For all statistical tests, the 0.05 level of confidence was accepted
for statistical significance.
siRNA Knockdown
The siRNAs used in this study were purchased from Healthcare/
Dharmacon: ON-TARGETplusHuman CHCHD2 siRNA SMARTpool
(cat. no L-019120-100005) andON-TARGETplusno-targeting siRNA
as a negative control (cat. no. D-001810-01-05). The siRNA was dis-
solved in 13 siRNA buffer and a final concentration of 50 nM was
transfected with lipofectamine RNAiMAX (13778150) in Opti-
MEM (11058021) following the manufacturer’s protocols (Thermo
Fischer Scientific).174 Stem Cell Reports j Vol. 13 j 163–176 j July 9, 2019Plasmid Preparation and In Vitro Transcription
of Capped mRNA
The synthetic gene encoding for CHCHD2was purchased from In-
tegrated DNA Technologies and cloned as NcoI-XhoI fragment in
the vector pEtheRNA-v2 as previously described (Van Lint et al.,
2016). In vitro mRNA transcription and quality controls were per-
formed as described in Bonehill et al. (2004). In brief, pEtheRNA-
v2 plasmid was linearized with BfuAI (Fermentas) and in vitro
mRNA transcription was performed with T7 polymerase according
to the manufacturer instructions. mRNA integrity, concentration,
and purity were tested on Agilent 2100 Bioanalyzer (Agilent
Technologies).
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